Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib

Astellas Pharma Inc. has fortified its oncology business by striking a deal to share development and commercialization of AVEO Pharmaceuticals Inc.'s Phase III cancer drug tivozanib in territories beyond Asia